Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 47.36 CNY -0.98% Market Closed
Market Cap: 59.9B CNY

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
¥355.1m
CAGR 3-Years
-40%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-¥1.3B
CAGR 3-Years
47%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
¥1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash from Operating Activities
-¥527.6m
CAGR 3-Years
19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Cash from Operating Activities
¥3.1B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Cash from Operating Activities
-¥429.8m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
59.9B CNY
Industry
Biotechnology

In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.

Beijing Wantai Biological Pharmacy Enterprise Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
355.1m CNY

Based on the financial report for Dec 31, 2024, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Operating Activities amounts to 355.1m CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
5%

Over the last year, the Cash from Operating Activities growth was -77%. The average annual Cash from Operating Activities growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been -40% over the past three years , 5% over the past five years .

Back to Top